Low plasma membrane expression of the miltefosine transport complex renders leishmania braziliensis refractory to the drug

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1305-1313

  Sánchez Cañete, María P ^a   Carvalho, Luís ^a   Pérez Victoria, F Javier ^a,b   Gamarro, Francisco ^a   Castanys, Santiago ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; LDMT PROTEIN; LDROS3 PROTEIN; MILTEFOSINE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG POTENCY; DRUG TRANSPORT; INTERNALIZATION; LEISHMANIA BRAZILIENSIS; NONHUMAN; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIPROTOZOAL AGENTS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; DRUG RESISTANCE; LEISHMANIA BRAZILIENSIS; MEMBRANE TRANSPORT PROTEINS; PHOSPHORYLCHOLINE; PROTOZOAN PROTEINS;

EID: 65649096220     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01694-08     Document Type: Article

References (23)

1. Araújo-Santos, J. M., F. Gamarro, S. Castanys, A. Herrmann, and T. Pomorski. 2003. Rapid transport of phospholipids across the plasma membrane of Leishmania infantum. Biochem. Biophys. Res. Commun. 306:250-255. (Pubitemid 36629433)
2. Bhattacharya, S. K., P. K. Sinha, S. Sundar, C. P. Thakur, T. K. Jha, K. Pandey, V. R. Das, N. Kumar, C. LaI, N. Verma, V. P. Singh, A. Ranjan, R. B. Verma, G. Anders, H. Sindermann, and N. K. Ganguly. 2007. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196:591-598. (Pubitemid 47206107)
3. Cabrera-Serra, M. G., J. Lorenzo-Morales, M. Romero, B. Valladares, and J. E. Pinero. 2007. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol. Res. 100: 1155-1157. (Pubitemid 46354882)
4. Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. RIjal, R. W. Peeling, J. Alvar, and M. Boelaert. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873-882. (Pubitemid 47578388)
5. Escobar, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157. (Pubitemid 34093805)
6. Ha, D. S., J. K. Schwarz, S. J. Turco, and S. M. Beverley. 1996. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol. Biochem. Parasitol. 77:57-64. (Pubitemid 26186162)
7. Lario, A, A. González, and G. Dorado. 1997. Automated laser-induced fluorescence DNA sequencing: equalizing signal-to-noise ratios significantly enhances overall performance. Anal. Biochem. 247:30-33. (Pubitemid 27161489)
8. Minodier, P., and P. Parola. 2007. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis. 5:150-158. (Pubitemid 46585958)
9. Mollinedo, F., J. L. Fernández-Luna, C. Gajate, B. Martín-Martín, A. Benito, R. Martínez-Dalmau, and M. Modolell. 1997. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (edelfosine): mo-lecular structure requirements, cellular uptake, and protection by Bcl-2 and BCI-XL. Cancer Res. 57:1320-1328. (Pubitemid 27152558)
10. Pérez-Victoria, F. J., S. Castanys, and F. Gamarro. 2003. Leishmania dono-vani resistance to miltefosine involves a defective inward translocation of the drag. Antimicrob. Agents Chemother. 47:2397-2403. (Pubitemid 36919436)
11. Pérez-Victoria, F. J., F. Gamarro, M. Ouellette, and S. Castanys. 2003. Functional cloning of the miltefosine transporter. A novel P-type phospho-lipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278:49965-49971. (Pubitemid 37548832)
12. Pérez-Victoria, F. J., M. P. Sánchez-Cañete, S. Castanys, and F. Gamarro. 2006. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem. 281:23766-23775. (Pubitemid 44274152)
13. Pérez-Victoria, F. J., M. P. Sánchez-Cañete, K. Seifert, S. L. Croft, S. Sundar, S. Castanys, and F. Gamarro. 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9:26-39. (Pubitemid 43928805)
14. Seifert, K., F. J. Pérez-Victoria, M. Stettier, M. P. Sánchez-Cañete, S. Cas-tanys, F. Gamarro, and S. L. Croft. 2007. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Anti-microb. Agents 30:229-235. (Pubitemid 47135625)
15. Small, G. W., J. C. Strum, and L. W. Daniel. 1997. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-0-methyl-rac-glycero-3-phosphocholine. Lipids 32:715-723. (Pubitemid 27328052)
16. Soto, J., B. A. Arana, J. Toledo, N. Rizzo, J. C. Vega, A. Diaz, M. Luz, P. Gutiérrez, M. Arboleda, J. D. Berman, K. Junge, J. Engel, and H. Sindermann. 2004. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38:1266-1272. (Pubitemid 38608569)
17. Soto, J., and J. Berman. 2006. Treatment of New World cutaneous leish-maniasis with miltefosine. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl. 1): S34-S40. (Pubitemid 44490170)
18. Soto, J., J. Toledo, L. Valda, M. Balderrama, I. Rea, R. Parra, J. Ardiles, P. Soto, A. Gómez, F. MoUeda, C. Fuentelsaz, G. Anders, H. Sindermann, J. Engel, and J. Berman. 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin. Infect. Dis. 44:350-356. (Pubitemid 46147616)
19. Soto, J., J. Rea, M. Balderrama, J. Toledo, P. Soto, L. Valda, and J. D. Berman. 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 78:210-211.
20. Sundar, S., A. Makharia, D. K. More, G. Agrawal, A. Voss, C. Fischer, P. Bachmann, and H. W. Murray. 2000. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31:1110-1113. (Pubitemid 32299377)
21. Sundar, S., T. K. Jha, C. P. Thakur, S. K. Bhattacharya, and M. Rai. 2006. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl. 1):S26-S33. (Pubitemid 44490165)
22. Yardley, V., S. L. Croft, S. De Doncker, J. C. Dujardin, S. Koirala, S. Rijal, C. Miranda, A. Llanos-Cuentas, and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73:272-275. (Pubitemid 41278697)
23. Zoeller, R. A., M. D. Layne, and E. J. Modest. 1995. Animal cell mutants unable to take up biologically active glycerophospholipids. J. Lipid Res. 36:1866-1875.